§ 522.2662

consumption; inject under the loose skin of the neck behind the head; if no improvement is noted within 5 days, diagnosis should be reevaluated; do not treat within 3 days of slaughter.

- (2) Turkeys—(i) Amount. 6.25 to 12.5 milligrams per sinus.
- (ii) Indications for use. As an aid in the control and treatment of infectious sinusitis caused by Mycoplasma gallisepticum sensitive to tylosin.
- (iii) Limitations. Do not use in laying turkeys producing eggs for human consumption; inject 6.25 milligrams to 12.5 milligrams per sinus depending on severity of condition; treatment may be repeated in 10 days if the swelling persists; do not treat within 5 days of slaughter; may be used in conjunction with tylosin in drinking water as indicated in §520.2640(e)(2) of this chapter.

 $[46\ FR\ 48643,\ Oct.\ 2,\ 1981,\ as\ amended\ at\ 50\ FR\ 49841,\ Dec.\ 5,\ 1985;\ 50\ FR\ 49841,\ Dec.\ 5,\ 1985;\ 59\ FR\ 14365,\ Mar.\ 28,\ 1994]$

§ 522.2662 Xylazine hydrochloride injection.

- (a) Specifications. Xylazine hydrochloride injection is a sterile aqueous solution containing xylazine hydrochloride equivalent to 100 milligrams of xylazine in each milliliter of solution when intended for use in horses, wild deer, and elk, and 20 milligrams of xylazine per milliliter of solution when intended for use in dogs and cats.
- (b) Sponsor. See 000856 in §510.600(c) of this chapter for use in horses, wild deer, and elk. See 000859 and 061651 in §510.600(c) of this chapter for use in horses, wild deer, elk, dogs, and cats. See 061690 in §510.600(c) of this chapter for use in horses, wild deer, elk, dogs, and cats. See 000010 in §510.600(c) of this chapter for use in horses only.
- (c) Conditions of use. (1) The drug is used in horses, wild deer, elk, dogs, and cats to produce sedation, as an analgesic, and a preanesthetic to local anesthesia. It may also be used in horses, dogs, and cats as a preanesthetic to general anesthesia.
 - (2) It is administered as follows:
- (i) To horses from a solution containing 100 milligrams of xylazine per milliliter, intravenously at 0.5 milligram per pound of body weight, or intramuscularly at 1.0 milligram per pound of body weight.

- (ii) To dogs and cats from a solution containing 20 milligrams of xylazine per milliliter; intravenously at 0.5 milligram per pound of body weight or intramuscularly or subcutaneously at 1.0 milligram per pound of body weight. In dogs over 50 pounds, a dosage of 0.5 mg. per pound administered intramuscularly may provide sufficient sedation and/or analgesia for most procedures.
- (iii) To wild deer and elk from a solution containing 100 milligrams of xylazine (as xylazine hydrochloride) per milliliter, intramuscularly, by hand syringe or syringe dart, in the heavy muscles of the croup or shoulder as follows:
- (a) Fallow deer, 2 to 4 milligrams per pound.
- (b) Mule deer, sika deer, and whitedeer, 1 to 2 milligrams per pound.
- (c) Elk, 0.25 to 0.5 milligram per pound.
- (3) Not to be administered to food-producing animals.
- (4) Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[40 FR 13858, Mar. 27, 1975, as amended at 41 FR 24884, June 21, 1976; 41 FR 28265, July 9, 1976; 53 FR 4848, Feb. 18, 1988; 53 FR 23608, June 23, 1988; 53 FR 40728, Oct. 18, 1988; 55 FR 18724, May 4, 1990; 55 FR 32616, Aug. 10, 1990; 59 FR 14367, Mar. 28, 1994; 60 FR 33110, June 27, 1995; 60 FR 35122 and 35123, July 6, 1995; 61 FR 46548, Sept. 4, 1996; 62 FR 35077, June 30, 1997]

§ 522.2670 Yohimbine injectable.

- (a) Specifications. Each milliliter of sterile aqueous solution contains either 2 or 5 milligrams of yohimbine (as hydrochloride).
- (b) Sponsor. See 061690 in \$510.600(c) of this chapter for use of 2 milligrams per milliliter solution in dogs.
- (1) Amount. 0.05 milligram per pound (0.11 milligram per kilogram) of body weight.
- (2) *Indications for use*. To reverse the effects of xylazine in dogs.
- (3) Limitations. For intravenous use in dogs only. Not for use in food-producing animals. Safety of use in pregnant dogs or in dogs intended for breeding has not been established. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Food and Drug Administration, HHS

- (c) Sponsor. See 053923 in §510.600(c) of this chapter for use of 5 milligrams per milliliter solution in deer and elk.
- (1) Amount. 0.2 to 0.3 milligram per kilogram of body weight.
- (2) Indications for use. As an antagonist to xylazine sedation in free ranging or confined members of the family Cervidae (deer and elk).
- (3) Limitations. For intravenous use only. Do not use in domestic food-producing animals. Do not use for 30 days before or during hunting season. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
- [58 FR 8543, Feb. 16, 1993, as amended at 60 FR 57832, Nov. 22, 1995]

§ 522.2680 Zeranol.

- (a) Specifications. Each pellet contains 12 milligrams of zeranol.
- (b) Sponsor. See 000061 in §510.600(c) of this chapter.
- (c) Related tolerances. See §556.760 of this chapter.
- (d) Conditions of use. For use as a subcutaneous ear implant as follows:
- (1) Beef cattle—(i) Amount. 36 milligrams (three 12-milligram pellets) per animal.
- (ii) Indications for use—(A) For increased rate of weight gain and improved feed conversion in weaned beef calves, growing beef cattle, feedlot steers, and feedlot heifers.
- (B) For increased rate of weight gain in suckling calves.
- Limitations. (iii) subcutaneously in ear only. Do not use in bulls intended for reproduction or in dairy animals. Do not use before 1 month of age or after weaning in heifers intended for reproduction.
- (2) Feedlot lambs—(i) Amount. 12 milligrams (1 pellet) per animal.
- (ii) Indications for use. For increased rate of weight gain and improved feed conversion.
- (iii) Limitations. Implant subcutaneously in ear only. Do not use in breeding animals. Do not implant animals within 40 days of slaughter.
- (3) Steers—(i) Amount. 72 milligrams (six 12-milligram pellets) per animal.
- (ii) Indications for use. For increased rate of weight gain and improved feed efficiency in steers fed in confinement for slaughter.

(iii) Limitations. Implant subcutaneously in ear only.

[59 FR 19639, Apr. 25, 1994; 60 FR 26360, May 17, 1995, as amended at 62 FR 61625, Nov. 19, 1997; 64 FR 46840, Aug. 27, 1999]

PART 524—OPHTHALMIC AND TOP-ICAL DOSAGE FORM NEW ANI-MAL DRUGS

524.86 Amitraz liquid.

- 524.154 Bacitracin or bacitracin zinc-neomycin sulfate-polymyxin B sulfate ophthalmic ointment.
- 524.155 Bacitracin zinc-polymyxin B sulfateneomycin sulfate-hydrocortisone or hydrocortisone acetate ophthalmic oint-
- 524.321 Cephalonium, polymyxin B sulfate, flumethasone, iodochlorhydroxyquin, piperocaine hydrochloride topical-otic ointment.
- 524.390 Chloramphenicol ophthalmic topical dosage forms.
- 524.390a Chloramphenicol ophthalmic ointment.
- 524.390b Chloramphenicol ophthalmic solution.
- 524.390c Chloramphenicol-prednisolone-tetracaine-squalane topical suspension.
- 524.390d Chloramphenicol-prednisolone ophthalmic ointment.
- 524.402 Chlorhexidine diacetate ointment.
- 524.450 Clotrimazole cream.
- 524.463 Copper naphthenate solution.
- 524.520 Cuprimyxin cream.
- 524.575 Cyclosporine ophthalmic ointment.
- 524.660 Dimethyl sulfoxide ophthalmic and topical dosage forms.
- 524.660a Dimethyl sulfoxide solution.
- 524.660b Dimethyl sulfoxide gel.
- 524.770 Doramectin.
- 524.802 Enrofloxacin. silver sulfadiazine emulsion.
- 524.814 Eprinomectin.
- 524 900 Famphur.
- 524.920 Fenthion.
- 524.960 Flumethasone, neomycin sulfate, and polymyxin B sulfate ophthalmic solutions
- 524.981 Fluocinolone acetonide ophthalmic and topical dosage forms.
- 524 981a Fluocinolone acetonide cream.
- 524.981b Fluocinolone acetonide solution.
- 524.981c Fluocinolone acetonide, neomycin sulfate cream.
- 524.981d Fluocinolone acetonide, dimethyl sulfoxide solution.
- 524.981e Fluocinolone acetonide, dimethyl sulfoxide otic solution.
- 524.1005 Furazolidone aerosol powder.
- 524.1044 Gentamicin sulfate ophthalmic and topical dosage forms.
- 524.1044a Gentamicin ophthalmic solution.